Steven Seedhouse
Stock Analyst at Raymond James
(3.44)
# 1,008
Out of 4,981 analysts
176
Total ratings
45.61%
Success rate
5.06%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $37.16 | +69.54% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $30.76 | +377.89% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $74.31 | +10.35% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.97 | +43.47% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $23.38 | +19.76% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $7.43 | +532.57% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.26 | +693.65% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $7.91 | +152.84% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $24.81 | +319.19% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.88 | +1,070.21% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $8.07 | +507.19% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.19 | +539.27% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $114.55 | -18.81% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $23.77 | +186.07% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $24.85 | +326.56% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.61 | +126.93% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $13.14 | +326.34% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.30 | +5,760.68% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $11.42 | +399.12% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $2.00 | +1,000.00% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.69 | +531.97% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.16 | +1,007.59% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $47.00 | -19.15% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $44.74 | +58.69% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $3.46 | +44.51% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $23.40 | +62.39% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.32 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.51 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.59 | +2,044.56% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $144.86 | - | 2 | Apr 23, 2020 |
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $37.16
Upside: +69.54%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $30.76
Upside: +377.89%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $74.31
Upside: +10.35%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.97
Upside: +43.47%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $23.38
Upside: +19.76%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $7.43
Upside: +532.57%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.26
Upside: +693.65%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $7.91
Upside: +152.84%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $24.81
Upside: +319.19%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.88
Upside: +1,070.21%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $8.07
Upside: +507.19%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.19
Upside: +539.27%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $114.55
Upside: -18.81%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $23.77
Upside: +186.07%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $24.85
Upside: +326.56%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.61
Upside: +126.93%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $13.14
Upside: +326.34%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.30
Upside: +5,760.68%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $11.42
Upside: +399.12%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $2.00
Upside: +1,000.00%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.69
Upside: +531.97%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.16
Upside: +1,007.59%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $47.00
Upside: -19.15%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $44.74
Upside: +58.69%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $3.46
Upside: +44.51%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $23.40
Upside: +62.39%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $17.32
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.51
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.59
Upside: +2,044.56%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $144.86
Upside: -